TG Therapeutics, Inc. (TGTX)
56.00
+1.63
(+3.00%)
USD |
NASDAQ |
Oct 15, 16:00
56.00
0.00 (0.00%)
After-Hours: 20:00
TG Therapeutics Cash from Operations (TTM) : 17.88M for June 30, 2026
Cash from Operations (TTM) Chart
Historical Cash from Operations (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 17.88M |
| March 31, 2026 | -13.95M |
| December 31, 2025 | -24.77M |
| September 30, 2025 | -70.07M |
| June 30, 2025 | -59.12M |
| March 31, 2025 | -61.02M |
| December 31, 2024 | -40.52M |
| September 30, 2024 | -28.09M |
| June 30, 2024 | 67.82M |
| March 31, 2024 | 20.28M |
| December 31, 2023 | -31.41M |
| September 30, 2023 | -42.07M |
| June 30, 2023 | -160.27M |
| March 31, 2023 | -167.38M |
| December 31, 2022 | -176.17M |
| September 30, 2022 | -239.21M |
| June 30, 2022 | -271.92M |
| March 31, 2022 | -282.97M |
| December 31, 2021 | -295.63M |
| September 30, 2021 | -260.75M |
| June 30, 2021 | -250.08M |
| March 31, 2021 | -233.75M |
| December 31, 2020 | -214.51M |
| September 30, 2020 | -192.87M |
| June 30, 2020 | -169.54M |
| Date | Value |
|---|---|
| March 31, 2020 | -161.57M |
| December 31, 2019 | -132.81M |
| September 30, 2019 | -136.10M |
| June 30, 2019 | -135.91M |
| March 31, 2019 | -134.23M |
| December 31, 2018 | -128.92M |
| September 30, 2018 | -117.09M |
| June 30, 2018 | -106.86M |
| March 31, 2018 | -99.50M |
| December 31, 2017 | -93.76M |
| September 30, 2017 | -88.93M |
| June 30, 2017 | -81.20M |
| March 31, 2017 | -67.22M |
| December 31, 2016 | -61.59M |
| September 30, 2016 | -57.46M |
| June 30, 2016 | -53.08M |
| March 31, 2016 | -52.48M |
| December 31, 2015 | -44.69M |
| September 30, 2015 | -46.89M |
| June 30, 2015 | -44.29M |
| March 31, 2015 | -35.61M |
| December 31, 2014 | -35.06M |
| September 30, 2014 | -24.86M |
| June 30, 2014 | -17.97M |
| March 31, 2014 | -16.95M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (TTM) Benchmarks
| Krystal Biotech, Inc. | 272.34M |
| Vertex Pharmaceuticals, Inc. | 4.293B |
| SELLAS Life Sciences Group, Inc. | -28.42M |
| Travere Therapeutics, Inc. | 92.70M |
| Alnylam Pharmaceuticals, Inc. | 885.89M |